Today, the COO of Merit Medical Systems (MMSI), Ronald Frost, sold shares of MMSI for $290.7K.
In addition to Ronald Frost, 4 other MMSI executives reported Sell trades in the last month. Over the last month, Ronald Frost has reported another 3 Sell trades on MMSI for a total of $453.7K.
See today’s analyst top recommended stocks >>
Based on Merit Medical Systems’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $222 million and quarterly net profit of $16.62 million. In comparison, last year the company earned revenue of $179 million and had a GAAP net loss of $3.57 million. MMSI’s market cap is $3.22B and the company has a P/E ratio of 79.33. Currently, Merit Medical Systems has an average volume of 113.3K.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $72.67, reflecting a 24.7% upside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy MMSI with a $75 price target.
In the last 30 days, insiders have sold $2.38M worth of MMSI shares and purchased $731.9K worth of MMSI shares. The insider sentiment on Merit Medical Systems has been neutral according to 22 insider trades in the past three months. This sentiment is equal to the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.
